Charles K S, Ramon L, Leelah N, Oluwabusi T A A, Seemungal T
Department of Paraclinical Sciences, Faculty of Medical Sciences, The University of the West Indies, St Augustine, Trinidad and Tobago.
West Indian Med J. 2011 Jun;60(3):298-302.
Data on the use of Imatinib (IM) in developing countries remain limited. A retrospective study was done to assess the efficacy and toxicity of IM in treating chronic myeloid leukaemia (CML) in Trinidad and Tobago.
Patients in all phases of CML who started IM therapy between February 2001 and February 2004 were included. All had received other previous therapy. They were assessed for haematological, cytogenetic and molecular response, overall survival (OS), event free survival (EFS) and adverse effects (AE).
Twenty-five patients were followed-up for a median 61 months. At initiation of IM, 18 were in the chronic phase (CP), 3 in accelerated phase (AP), 3 in blast crisis (BC) and one in myelofibrotic transformation (MF). Overall, 96% of patients achieved complete haematological remission (CHR). Among CP patients, 67% attained a major cytogenetic response (MCR) and 44% a complete cytogenetic response (CCR). Overall survival and event free survival in the CP group were 82% and 76% respectively. Overall survival for advanced phase patients was 14% at 61 months. The adverse effects of IM were the same as previously described and generally tolerable. No patient opted to discontinue IM because of side effects.
After 5 years of follow-up, IM was found to induce favourable and durable survival responses with an acceptable side effect profile in CP-CML patients who had received prior treatment with alternative agents.
关于伊马替尼（IM）在发展中国家使用的数据仍然有限。开展了一项回顾性研究，以评估IM在特立尼达和多巴哥治疗慢性粒细胞白血病（CML）的疗效和毒性。
纳入2001年2月至2004年2月开始接受IM治疗的所有CML分期患者。所有患者此前均接受过其他治疗。对他们进行血液学、细胞遗传学和分子反应、总生存期（OS）、无事件生存期（EFS）及不良反应（AE）评估。
25例患者接受了中位61个月的随访。开始使用IM时，18例处于慢性期（CP），3例处于加速期（AP），3例处于急变期（BC），1例处于骨髓纤维化转化期（MF）。总体而言，96%的患者实现了完全血液学缓解（CHR）。在CP期患者中，67%达到主要细胞遗传学反应（MCR），44%达到完全细胞遗传学反应（CCR）。CP组的总生存期和无事件生存期分别为82%和76%。晚期患者61个月时的总生存期为14%。IM的不良反应与先前描述的相同，且一般可耐受。没有患者因副作用而选择停用IM。
经过5年的随访，发现IM在接受过其他替代药物治疗的CP-CML患者中可诱导良好且持久的生存反应，且副作用可接受。
